you can't compare a non-placebo controlled, epo allowed, 48 wk trial with another placebo controlled, epo not allowed, 24 wk trial.
That's funny! I'm sure the ppl who tx'ed with boceprevir will be cheering on their trial drug as well. That's why it would be really good for a neutral party to run them neck and neck and let us heppers know which one is truly the best. Maybe in 5yrs or so we will see a competitive commercial on tv. How's that sound blue bomber ppl? Anyone?
Keeping my fingers crossed. Go, Telaprevir!
The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR)
---------------------------------------------------------------------------------------------------------------------------
Interesting article, I wonder if there will ever be a "Consumer Reports" type of trial done to determine which PI works best? It appears by the above that Shering is doing a really good job of tooting their horn as well. It will be interesting to read in one article which PI has the least amount of sx's and overall success rate against tx naive's, relapsers, previous non-responders etc. Maybe in a couple of years there will be a television commercial for PI's like a McDonalds commercial being better than BurgerKing.lol We'll have to see. good news for all heppers either way
http://www.medscape.com/viewarticle/701971
http://www.freshnews.com/node/133714